Question-and-Answer Session
Operator
(Operator instructions) Our first question this afternoon will come from Joel Sendek with Lazard Capital Markets.
Joel Sendek – Lazard Capital Markets
Hi, thanks. I have two questions. First of all, can you just go over what your registration strategy is for TRU-015 at this point?
Peter Thompson
Joel thanks for the question. I’ll let Scott Stromatt address that.
Scott Stromatt
Thank you. The current registration strategy is within the conjunction with our partner, Wyeth. The initial indication would be an RA. Phase 2b study has started, which is referred to as 2203, and that is on going. And after that, we will be probably starting on the Phase 3 trial in about 2010.
Joel Sendek – Lazard Capital Markets
And can you – might the 2b be a pivotal trial? You’ve mentioned that in the past or is that a –?
Scott Stromatt
Yes, it would absolutely be a supporting trial.
Joel Sendek – Lazard Capital Markets
Supporting? Would that be enough or would you need the Phase 3 as well?
Scott Stromatt
I think it depends on the quality of the results. Potentially, it could be enough, but I think from a registration standpoint in RA, you’ll need two trials.
Joel Sendek – Lazard Capital Markets
Okay, thanks. And then just on the burn rate. This would give you a little bit more runway, so what do you have, about two years at this point? Is that a fair estimate?
Peter Thompson
I’ll let you take that question.
Michelle Burris
Well, I think, obviously, the – if you look through our SEC filings, we say we have an excess of 12 months. Obviously, how aggressive we are in pursuing our clinical development plans for 016 as well as our other research and preclinical activities will drive that burn rate.
Joel Sendek – Lazard Capital Markets
Okay, that’s it. Thanks.
Operator
(Operator instructions) We move now to Steve Harr with Morgan Stanley.
Steve Harr – Morgan Stanley
Hi, good afternoon, guys. So this re-treatment, it was every six months with – were you seeing B-cells replete in between each treatment? Or how did you treat patients whose B-cells remained low at six months?
Peter Thompson
Steve or Dr. Harr, thanks a lot for the (inaudible). Scott, answer that.
Scott Stromatt
The B-cells, we didn’t announce those results in the press release, and so I think basically, we’ll have that in the poster that we’ll probably present at EULAR in the summer in June. Suffice it to say, just the timing patients retreated and the pattern of B-cell repletion is similar to what we saw with the initial treatment.
- To read the full transcript on Seeking Alpha, click here »
